Atara Biotherapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Atara Biotherapeutics, Inc. on February 6, 2017. The report discloses a corporate governance event regarding the approval of discretionary cash bonus payments to executive officers for performance during the 2016 calendar year.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific executive compensation payments approved by the Compensation Committee.
| Executive Name | Title | Discretionary Bonus (2016) |
|---|---|---|
| Isaac Ciechanover | Chief Executive Officer | $270,270 |
| Christopher Haqq | Executive Vice President, Chief Scientific Officer | $154,752 |
| Heather Turner | Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy | $127,592 |
Material Changes
The filing reports no material changes to the company's financial condition or operations compared to prior periods. The sole material event is the authorization of the aforementioned bonus payments.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies. The bonuses were awarded in recognition of the Company's performance during 2016, though specific performance metrics driving the awards are not detailed in this text.
Key Facts for Investor Verification
- Verify the total amount of discretionary bonuses paid to named executive officers for 2016 ($552,614 total).
- Confirm the specific performance criteria used by the Compensation Committee to determine these bonus amounts.
- Review the company's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K does not contain revenue or cash flow figures.